News

Back from the 2015 ISTRY conference, we would like to thanks the organizers for this fruitful event and congratulate the winners of our quizz.

ImmuSmol CEO Alban Bessede has contributed to a recent paper in Obesity : “The kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation.”

ImmuSmol is sponsoring the 2015 conference of the International Society for Tryptophan Research, taking place on September 16-18, at the Van Andel Research Institute in Grand Rapids, Michigan, USA.

A recent PLOS ONE article shows that ImmuSmol’s anti-L-Kynurenine-antibody can serve to stratify cancer patients for kynurenine pathway activity. Access the article…

ImmuSmol is sponsoring the Symposium “The immune-brain axis: from molecules to behavior”, held at the Hasselt University, Campus Diepenbeek, Belgium, on March 12th and 13th, 2015.

Discover ImmuSmol’s story, featured in the 2015 winter edition of the European Biotechnology Magazine.

Just a few words to thank our clients and partners and wish them a bright and joyful 2015.

ImmuSmol is pleased to announce it has raised 500 000 € to progress its monoclonal antibodies for cancer immunotherapy to in vivo proof-of-concept (POC).

Access latest article by ImmuSmol CEO Alban Bessède

NEW! ImmuSmol releases rabbit polyclonal antibodies against Tryptophan / Kynurenine metabolites, all validated for IHC in human samples.

Picture: L-Kynurenine detection by IHC in human colorectal cancer tissue using anti-L-Kynurenine rabbit pAb.

ImmuSmol will be in Turin for Bioeurope Spring 2014, on March 10-12. Contact us to arrange a meeting!

A short overview of ImmuSmol’s services for the development of antibodies against small molecules, and their subsequent validation for small molecule detection by ELISA or IHC.